Real World Assessment of clinical outcome changes -including month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Trial Identifier: D1690R00028
Sponsor: AstraZeneca
NCTID:: NCT02805361
Start Date: August 2016
Primary Completion Date: July 2018
Study Completion Date: July 2018
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Kuwait Kuwait City, Kuwait
United Arab Emirates Abu Dhabi, United Arab Emirates
United Arab Emirates Ajman, United Arab Emirates
United Arab Emirates Dubai, United Arab Emirates